Atsena Therapeutics

We’re proud to announce that dosing has been completed in Part A of the LIGHTHOUSE study, our Phase I/II clinical trial evaluating ATSN-201, our best-in-class #GeneTherapy product candidate to treat X-linked retinoschisis (#XLRS). Completing this critical milestone represents a step forward to providing a transformative therapy to patients living with this #InheritedRetinalDisease, which has no approved treatments.   ATSN-201 leverages our novel spreading capsid, AAV.SPR, which creates an innovative approach that achieves therapeutic levels of gene expression in the photoreceptors of the central retina while avoiding the surgical risks associated with foveal detachment.    Stay tuned for more updates as we advance the LIGHTHOUSE study next year! Learn more here: https://lnkd.in/eMsmFaxJ   Visual description: The image features a headshot of Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics. The headshot is framed within a stylized circular border with gradient shades of orange, purple, and blue. To the right of the image is a quotation in white text on a purple-to-blue gradient background with dotted patterns. The text reads: "Collecting data from Part A of the trial is an important breakthrough for Atsena because it validates the use of our novel capsid to effectively treat inherited retinal disease and it informs the safest and most effective path forward for Part B. We look forward to providing further updates from those patients early next year." — Kenji Fujita, MD, Chief Medical Officer The bottom right corner includes the Atsena Therapeutics logo in blue and white next to the company name.

We're excited to share this Cell & Gene article authored by Atsena co-founder Sanford Boye that highlights our pioneering work to address a critical challenge in gene therapy: achieving effective transduction across the retina.   This innovative approach to treating the #InheritedRetinalDisease X-linked retinoschisis (#XLRS) leverages a unique AAV capsid engineered for robust subretinal spread. This breakthrough enables efficient delivery of the therapeutic gene to target cells across the retina, offering hope to patients impacted by this vision-debilitating condition.   Read more about how our science is shaping the future of ocular #GeneTherapy: https://lnkd.in/ewThiuYy

Co-founder and Advisor Sanford Boye is presenting today at the 45th Annual Meeting of the American College of Toxicology (ACT)! His presentation will spotlight key insights in preclinical toxicology for #ocular gene therapies, including the development of our best-in-class #genetherapy candidate, ATSN-201, designed to treat X-linked retinoschisis (#XLRS).   Follow #ACTOX2024 for more updates!   https://lnkd.in/e5653jME  

Our Senior Medical Director, Dr. Dan Yoon, represented Atsena during the Association for Research in Vision and Ophthalmology (ARVO) Frontiers in Ocular Gene Therapy Research virtual conference! The conference gathered industry experts and innovators to discuss the latest #ocular innovations and treatments.   Dr. Yoon shared insights from the 12-month safety and efficacy data of our first-in-class, investigational ocular #GeneTherapy, ATSN-101, to treat patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (#LCA1). 

Nippon Shinyaku and Atsena Therapeutics collaborate on ATSN-101 Read the article: https://lnkd.in/eT7y5G7j

🔬 Atsena Therapeutics & Nippon Shinyaku Partner to Advance Gene Therapy for LCA1 Atsena Therapeutics and Nippon Shinyaku have entered an exclusive agreement to develop and commercialize ATSN-101, a first-of-its-kind gene therapy for Leber congenital amaurosis type 1 (LCA1), in the U.S. and Japan. This partnership brings ATSN-101 closer to becoming a transformative treatment for patients with LCA1, a rare retinal disease with no current therapies. “This agreement accelerates ATSN-101’s development and validates Atsena’s pioneering technology,” said Atsena CEO Patrick Ritschel. Nippon Shinyaku President Toru Nakai added, “We are excited to partner with Atsena and contribute to their groundbreaking science.” 🔗Discover how this partnership is advancing gene therapy for retinal disease: https://lnkd.in/gQ5BZge4 #Collaboration #GeneTherapy #EyeDisease #Ophthalmology #Innovation

Nippon Shinyaku, a pharmaceutical company based in Kyoto, Japan, and Atsena Therapeutics, a developer of gene therapies for retinal diseases in Durham, North Carolina, have entered into a license agreement for the commercialization of ATSN-101, an emerging gene therapy for Leber congenital amaurosis 1 (LCA1) which is caused by mutations in the gene GUCY2D. Read more at: https://bit.ly/3YO1mRT

Nippon Shinyaku and Atsena Therapeutics have entered into an exclusive strategic collaboration for ATSN-101 in the U.S. and Japan. Read more at: https://bit.ly/4eoDH0c

We’re excited to share the news that our parent company Nippon Shinyaku has entered into an exclusive license agreement with Atsena Therapeutics to commercialize its ATSN-101 therapy in the United States and Japan! ATSN-101 is a first-in-class, investigational #genetherapy for the treatment of Leber congenital amaurosis (LCA1). LCA1 is a rare eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness. Read more in our press release: https://ow.ly/tFQx50U6nK2 #opthalmology #raredisease #lebers

#NipponShinyaku and Atsena Therapeutics Join Forces to Commercialize ATSN-101 Across the US and Japan #nipponshinyaku #atsenatherapeutics #atsn101 #lebercongenitalamaurosis #pharma #pharmashots